Brivaracetam in Unverricht‐Lundborg disease (EPM 1): Results from two randomized, double‐blind, placebo‐controlled studies
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Objective: To evaluate efficacy, tolerability, and safety of adjunctive brivaracetam (BRV) in patients with Unverricht‐Lundborg disease (EPM 1). Methods: Two prospective, multicenter, double‐blind, phase III trials (N01187/NCT 00357669; N01236/NCT 00368251) in patients (≥16 years) with genetically ascertained EPM 1, showing moderate–severe myoclonus (action myoclonus score ≥30/160), randomized (1:1:1) to twice‐daily BRV (N01187: 50 or 150 mg/day; N01236: 5 or 150 mg/day), or placebo. Both studies comprised a baseline period (2 weeks), 2‐week up‐titration period, 12‐week stable‐dose maintenance period, and down‐titration or entry into long‐term follow‐up study. Symptoms of myoclonus were assessed by Unified Myoclonus Rating Scale (UMRS). Primary efficacy end point was percent reduction from baseline in action myoclonus score (UMRS section 4) at last treatment visit. Safety assessments included treatment‐emergent adverse events (TEAE s). Results: N01187: 50 patients randomized, 47 completed; N01236: 56 patients randomized, 54 completed. Median (min–max) percent reduction from baseline in action myoclonus score is the following—N01187: placebo 5.6 (−81.3 to 53.8), pooled BRV group (primary efficacy analysis) 21.4 (−50.0 to 73.6), BRV 50 mg/day 26.3 (−35.8 to 69.2), BRV 150 mg/day 16.9 (−50.0 to 73.6); N01236: placebo 17.5 (−170 to 61.5), BRV 5 mg/day −4.6 (−430 to 81.8), BRV 150 mg/day (primary efficacy analysis) 12.3 (−58.3 to 96.9). Estimated differences versus placebo were not statistically significant. TEAE s were reported by 72–75% placebo‐treated and 56–83% BRV‐treated patients. Significance: Effect of BRV on action myoclonus was not statistically significant. However, action myoclonus score showed wide intrapatient variability and may not have been the optimal tool to measure severity of myoclonus in EPM 1. Both studies had very high completion rates (95.3% overall), and a high percentage of patients (88.7% overall) entered long‐term follow‐up; both likely to be influenced by good tolerability. These studies demonstrate the feasibility of rigorous trials in progressive myoclonic epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“It is notable that a majority of patients were subject to treatment with piracetam and/or LEV, both SV2A ligands.(39,40) Indeed, clinicians have noted that previous treatment with piracetam mitigates the effects of LEV in EPM1.”
Background
Cited by
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99
A review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
“Patients with Unverricht–Lundborg disease Two Phase III studies (NCT00357669 and NCT00368251) were conducted in patients with Unverricht–Lundborg disease (also called epilepsy with progressive myoclonus type I [EPM1]).(102) In two randomized, double-blind, placebocontrolled, multicenter studies, patients aged ≥16 year…”
MethodWu, P.-P., Cao, B.-R., Tian, F.-Y., & Gao, Z.-B. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-023-01138-2 · Cited by 35
Metadata
- Authors
- Kälviäinen, R., Genton, P., Andermann, E., Andermann, F., Magaudda, A., Frucht, S. J., Schlit, A., Gerard, D., de la Loge, C., & von Rosenstiel, P.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2015-12-15
- Volume
- 57
- Issue
- 2
- Pages
- 210-221
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2210712732
- Cited by
- 53
- References
- 1
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.